Povorcitinib Enrolls First Patient in China Phase III Trial
China Medical System said its oral vitiligo drug povorcitinib has enrolled its first patient in a Phase III clinical trial in China.
China Medical System said its oral vitiligo drug povorcitinib has enrolled its first patient in a Phase III clinical trial in China.